APO Research
Talk to an analyst

APO RESEARCH · REPORT

Injectable Drugs For Type-2 Diabete

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Injectable Drugs For Type-2 Diabete Market Analysis and Forecast 2026-2032

2 January 2026199 pages

Choose your research edition.

Industry ResearchInjectable Drugs For Type-2 Diabete Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal Injectable Drugs For Type-2 Diabete Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Injectable Drugs For Type-2 Diabete Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Injectable Drugs For Type-2 Diabete Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Injectable Drugs For Type-2 Diabete Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Injectable Drugs For Type-2 Diabete market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Injectable Drugs For Type-2 Diabete is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Injectable Drugs For Type-2 Diabete is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Injectable Drugs For Type-2 Diabete is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Injectable Drugs For Type-2 Diabete is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Injectable Drugs For Type-2 Diabete include Sanofi, Merck, Eli Lilly, GSK, AstraZeneca, Novo Nordisk and Boehringer Ingelheim, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Injectable Drugs For Type-2 Diabete, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Injectable Drugs For Type-2 Diabete, also provides the revenue of main regions and countries. Of the upcoming market potential for Injectable Drugs For Type-2 Diabete, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Injectable Drugs For Type-2 Diabete revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Injectable Drugs For Type-2 Diabete market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Injectable Drugs For Type-2 Diabete revenue, projected growth trends, production technology, application and end-user industry.

Injectable Drugs For Type-2 Diabete Segment by Company

Sanofi

Merck

Eli Lilly

GSK

AstraZeneca

Novo Nordisk

Boehringer Ingelheim

Injectable Drugs For Type-2 Diabete Segment by Type

Exenatide

Liragultide

Pramlintide

Insulin

Others

Injectable Drugs For Type-2 Diabete Segment by Application

Retail Pharmacy

Online Pharmacy

Hospital Pharmacy

Others

Injectable Drugs For Type-2 Diabete Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Injectable Drugs For Type-2 Diabete market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Injectable Drugs For Type-2 Diabete and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Injectable Drugs For Type-2 Diabete.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Injectable Drugs For Type-2 Diabete in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Injectable Drugs For Type-2 Diabete company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Injectable Drugs For Type-2 Diabete revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Injectable Drugs For Type-2 Diabete Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Exenatide Major Player Table 3. Liragultide Major Player Table 4. Pramlintide Major Player Table 5. Insulin Major Player Table 6. Others Major Player Table 7. Global Injectable Drugs For Type-2 Diabete Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Retail Pharmacy Major Player Table 9. Online Pharmacy Major Player Table 10. Hospital Pharmacy Major Player Table 11. Others Major Player Table 12. Injectable Drugs For Type-2 Diabete Industry Trends Table 13. Injectable Drugs For Type-2 Diabete Industry Drivers Table 14. Injectable Drugs For Type-2 Diabete Industry Opportunities and Challenges Table 15. Injectable Drugs For Type-2 Diabete Industry Restraints Table 16. Global Injectable Drugs For Type-2 Diabete Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 17. Global Injectable Drugs For Type-2 Diabete Market Size by Region (2021-2026) & (US$ Million) Table 18. Global Injectable Drugs For Type-2 Diabete Market Share by Region (2021-2026) Table 19. Global Injectable Drugs For Type-2 Diabete Market Size by Region (2027-2032) & (US$ Million) Table 20. Global Injectable Drugs For Type-2 Diabete Market Share by Region (2027-2032) Table 21. Global Injectable Drugs For Type-2 Diabete Revenue by Players (US$ Million) & (2021-2026) Table 22. Global Injectable Drugs For Type-2 Diabete Revenue Market Share by Players (2021-2026) Table 23. Global Injectable Drugs For Type-2 Diabete Key Players Ranking, 2024 VS 2025 VS 2026 Table 24. Global Injectable Drugs For Type-2 Diabete Key Players Headquarters & Area Served Table 25. Global Injectable Drugs For Type-2 Diabete Players, Product Type & Application Table 26. Global Injectable Drugs For Type-2 Diabete Players Establishment Date Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Injectable Drugs For Type-2 Diabete by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Global Injectable Drugs For Type-2 Diabete Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Injectable Drugs For Type-2 Diabete Revenue by Type (2021-2026) & (US$ Million) Table 31. Global Injectable Drugs For Type-2 Diabete Revenue by Type (2027-2032) & (US$ Million) Table 32. Global Injectable Drugs For Type-2 Diabete Revenue Market Share by Type (2021-2026) Table 33. Global Injectable Drugs For Type-2 Diabete Revenue Market Share by Type (2027-2032) Table 34. Global Injectable Drugs For Type-2 Diabete Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Injectable Drugs For Type-2 Diabete Revenue by Application (2021-2026) & (US$ Million) Table 36. Global Injectable Drugs For Type-2 Diabete Revenue by Application (2027-2032) & (US$ Million) Table 37. Global Injectable Drugs For Type-2 Diabete Revenue Market Share by Application (2021-2026) Table 38. Global Injectable Drugs For Type-2 Diabete Revenue Market Share by Application (2027-2032) Table 39. Sanofi Company Information Table 40. Sanofi Business Overview Table 41. Sanofi Injectable Drugs For Type-2 Diabete Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Sanofi Injectable Drugs For Type-2 Diabete Product Portfolio Table 43. Sanofi Recent Development Table 44. Merck Company Information Table 45. Merck Business Overview Table 46. Merck Injectable Drugs For Type-2 Diabete Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Merck Injectable Drugs For Type-2 Diabete Product Portfolio Table 48. Merck Recent Development Table 49. Eli Lilly Company Information Table 50. Eli Lilly Business Overview Table 51. Eli Lilly Injectable Drugs For Type-2 Diabete Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Eli Lilly Injectable Drugs For Type-2 Diabete Product Portfolio Table 53. Eli Lilly Recent Development Table 54. GSK Company Information Table 55. GSK Business Overview Table 56. GSK Injectable Drugs For Type-2 Diabete Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. GSK Injectable Drugs For Type-2 Diabete Product Portfolio Table 58. GSK Recent Development Table 59. AstraZeneca Company Information Table 60. AstraZeneca Business Overview Table 61. AstraZeneca Injectable Drugs For Type-2 Diabete Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. AstraZeneca Injectable Drugs For Type-2 Diabete Product Portfolio Table 63. AstraZeneca Recent Development Table 64. Novo Nordisk Company Information Table 65. Novo Nordisk Business Overview Table 66. Novo Nordisk Injectable Drugs For Type-2 Diabete Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Novo Nordisk Injectable Drugs For Type-2 Diabete Product Portfolio Table 68. Novo Nordisk Recent Development Table 69. Boehringer Ingelheim Company Information Table 70. Boehringer Ingelheim Business Overview Table 71. Boehringer Ingelheim Injectable Drugs For Type-2 Diabete Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Boehringer Ingelheim Injectable Drugs For Type-2 Diabete Product Portfolio Table 73. Boehringer Ingelheim Recent Development Table 74. North America Injectable Drugs For Type-2 Diabete Revenue by Type (2021-2026) & (US$ Million) Table 75. North America Injectable Drugs For Type-2 Diabete Revenue by Type (2027-2032) & (US$ Million) Table 76. North America Injectable Drugs For Type-2 Diabete Revenue by Application (2021-2026) & (US$ Million) Table 77. North America Injectable Drugs For Type-2 Diabete Revenue by Application (2027-2032) & (US$ Million) Table 78. North America Injectable Drugs For Type-2 Diabete Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 79. North America Injectable Drugs For Type-2 Diabete Revenue by Country (2021-2026) & (US$ Million) Table 80. North America Injectable Drugs For Type-2 Diabete Revenue by Country (US$ Million) & (2027-2032) Table 81. Europe Injectable Drugs For Type-2 Diabete Revenue by Type (2021-2026) & (US$ Million) Table 82. Europe Injectable Drugs For Type-2 Diabete Revenue by Type (2027-2032) & (US$ Million) Table 83. Europe Injectable Drugs For Type-2 Diabete Revenue by Application (2021-2026) & (US$ Million) Table 84. Europe Injectable Drugs For Type-2 Diabete Revenue by Application (2027-2032) & (US$ Million) Table 85. Europe Injectable Drugs For Type-2 Diabete Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 86. Europe Injectable Drugs For Type-2 Diabete Revenue by Country (2021-2026) & (US$ Million) Table 87. Europe Injectable Drugs For Type-2 Diabete Revenue by Country (US$ Million) & (2027-2032) Table 88. China Injectable Drugs For Type-2 Diabete Revenue by Type (2021-2026) & (US$ Million) Table 89. China Injectable Drugs For Type-2 Diabete Revenue by Type (2027-2032) & (US$ Million) Table 90. China Injectable Drugs For Type-2 Diabete Revenue by Application (2021-2026) & (US$ Million) Table 91. China Injectable Drugs For Type-2 Diabete Revenue by Application (2027-2032) & (US$ Million) Table 92. Asia Injectable Drugs For Type-2 Diabete Revenue by Type (2021-2026) & (US$ Million) Table 93. Asia Injectable Drugs For Type-2 Diabete Revenue by Type (2027-2032) & (US$ Million) Table 94. Asia Injectable Drugs For Type-2 Diabete Revenue by Application (2021-2026) & (US$ Million) Table 95. Asia Injectable Drugs For Type-2 Diabete Revenue by Application (2027-2032) & (US$ Million) Table 96. Asia Injectable Drugs For Type-2 Diabete Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 97. Asia Injectable Drugs For Type-2 Diabete Revenue by Region (US$ Million) & (2021-2026) Table 98. Asia Injectable Drugs For Type-2 Diabete Revenue by Region (US$ Million) & (2027-2032) Table 99. SAMEA Injectable Drugs For Type-2 Diabete Revenue by Type (2021-2026) & (US$ Million) Table 100. SAMEA Injectable Drugs For Type-2 Diabete Revenue by Type (2027-2032) & (US$ Million) Table 101. SAMEA Injectable Drugs For Type-2 Diabete Revenue by Application (2021-2026) & (US$ Million) Table 102. SAMEA Injectable Drugs For Type-2 Diabete Revenue by Application (2027-2032) & (US$ Million) Table 103. SAMEA Injectable Drugs For Type-2 Diabete Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 104. SAMEA Injectable Drugs For Type-2 Diabete Revenue by Country (2021-2026) & (US$ Million) Table 105. SAMEA Injectable Drugs For Type-2 Diabete Revenue by Country (US$ Million) & (2027-2032) Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. Injectable Drugs For Type-2 Diabete Image Figure 2. Global Injectable Drugs For Type-2 Diabete Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Injectable Drugs For Type-2 Diabete Market Size Share 2021 VS 2025 VS 2032 Figure 4. Exenatide Image Figure 5. Liragultide Image Figure 6. Pramlintide Image Figure 7. Insulin Image Figure 8. Others Image Figure 9. Global Injectable Drugs For Type-2 Diabete Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Injectable Drugs For Type-2 Diabete Market Size Share 2021 VS 2025 VS 2032 Figure 11. Retail Pharmacy Image Figure 12. Online Pharmacy Image Figure 13. Hospital Pharmacy Image Figure 14. Others Image Figure 15. Global Injectable Drugs For Type-2 Diabete Market Size (US$ Million) & (2021-2032) Figure 16. Global Injectable Drugs For Type-2 Diabete Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Injectable Drugs For Type-2 Diabete Market Share by Region: 2021 VS 2025 VS 2032 Figure 18. Global Injectable Drugs For Type-2 Diabete Players Revenue Share Top 10 and Top 5 in 2025 Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Injectable Drugs For Type-2 Diabete Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Injectable Drugs For Type-2 Diabete Revenue Market Share 2021 VS 2025 VS 2032 Figure 22. Global Injectable Drugs For Type-2 Diabete Revenue Market Share by Type (2021-2032) Figure 23. Global Injectable Drugs For Type-2 Diabete Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Injectable Drugs For Type-2 Diabete Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 25. Global Injectable Drugs For Type-2 Diabete Revenue Market Share by Application (2021-2032) Figure 26. North America Injectable Drugs For Type-2 Diabete Revenue YoY Growth (2021-2032) & (US$ Million) Figure 27. North America Injectable Drugs For Type-2 Diabete Revenue Share by Type (2021-2032) Figure 28. North America Injectable Drugs For Type-2 Diabete Revenue Share by Application (2021-2032) Figure 29. North America Injectable Drugs For Type-2 Diabete Revenue Share by Country (2021-2032) Figure 30. United States Injectable Drugs For Type-2 Diabete Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Canada Injectable Drugs For Type-2 Diabete Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Mexico Injectable Drugs For Type-2 Diabete Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Europe Injectable Drugs For Type-2 Diabete Revenue YoY Growth (2021-2032) & (US$ Million) Figure 34. Europe Injectable Drugs For Type-2 Diabete Revenue Share by Type (2021-2032) Figure 35. Europe Injectable Drugs For Type-2 Diabete Revenue Share by Application (2021-2032) Figure 36. Europe Injectable Drugs For Type-2 Diabete Revenue Share by Country (2021-2032) Figure 37. Germany Injectable Drugs For Type-2 Diabete Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. France Injectable Drugs For Type-2 Diabete Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. U.K. Injectable Drugs For Type-2 Diabete Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Italy Injectable Drugs For Type-2 Diabete Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Spain Injectable Drugs For Type-2 Diabete Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Russia Injectable Drugs For Type-2 Diabete Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Netherlands Injectable Drugs For Type-2 Diabete Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Nordic Countries Injectable Drugs For Type-2 Diabete Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. China Injectable Drugs For Type-2 Diabete Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. China Injectable Drugs For Type-2 Diabete Revenue Share by Type (2021-2032) Figure 47. China Injectable Drugs For Type-2 Diabete Revenue Share by Application (2021-2032) Figure 48. Asia Injectable Drugs For Type-2 Diabete Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. Asia Injectable Drugs For Type-2 Diabete Revenue Share by Type (2021-2032) Figure 50. Asia Injectable Drugs For Type-2 Diabete Revenue Share by Application (2021-2032) Figure 51. Asia Injectable Drugs For Type-2 Diabete Revenue Share by Region (2021-2032) Figure 52. Japan Injectable Drugs For Type-2 Diabete Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. South Korea Injectable Drugs For Type-2 Diabete Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. India Injectable Drugs For Type-2 Diabete Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Australia Injectable Drugs For Type-2 Diabete Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Taiwan Injectable Drugs For Type-2 Diabete Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Southeast Asia Injectable Drugs For Type-2 Diabete Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. SAMEA Injectable Drugs For Type-2 Diabete Revenue YoY Growth (2021-2032) & (US$ Million) Figure 59. SAMEA Injectable Drugs For Type-2 Diabete Revenue Share by Type (2021-2032) Figure 60. SAMEA Injectable Drugs For Type-2 Diabete Revenue Share by Application (2021-2032) Figure 61. SAMEA Injectable Drugs For Type-2 Diabete Revenue Share by Country (2021-2032) Figure 62. Brazil Injectable Drugs For Type-2 Diabete Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Argentina Injectable Drugs For Type-2 Diabete Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Chile Injectable Drugs For Type-2 Diabete Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Colombia Injectable Drugs For Type-2 Diabete Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Peru Injectable Drugs For Type-2 Diabete Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Saudi Arabia Injectable Drugs For Type-2 Diabete Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Israel Injectable Drugs For Type-2 Diabete Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. UAE Injectable Drugs For Type-2 Diabete Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Turkey Injectable Drugs For Type-2 Diabete Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Iran Injectable Drugs For Type-2 Diabete Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Egypt Injectable Drugs For Type-2 Diabete Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Exenatide
  • Liragultide
  • Pramlintide
  • Insulin
  • Others
Applications
  • Retail Pharmacy
  • Online Pharmacy
  • Hospital Pharmacy
  • Others
Companies covered
  • Sanofi
  • Merck
  • Eli Lilly
  • GSK
  • AstraZeneca
  • Novo Nordisk
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Injectable Drugs For Type-2 Diabete Market by Type
  3. 1.2.1 Global Injectable Drugs For Type-2 Diabete Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Exenatide
  5. 1.2.3 Liragultide
  6. 1.2.4 Pramlintide
  7. 1.2.5 Insulin
  8. 1.2.6 Others
  9. 1.3 Injectable Drugs For Type-2 Diabete Market by Application
  10. 1.3.1 Global Injectable Drugs For Type-2 Diabete Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Retail Pharmacy
  12. 1.3.3 Online Pharmacy
  13. 1.3.4 Hospital Pharmacy
  14. 1.3.5 Others
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Injectable Drugs For Type-2 Diabete Market Dynamics
  1. 2.1 Injectable Drugs For Type-2 Diabete Industry Trends
  2. 2.2 Injectable Drugs For Type-2 Diabete Industry Drivers
  3. 2.3 Injectable Drugs For Type-2 Diabete Industry Opportunities and Challenges
  4. 2.4 Injectable Drugs For Type-2 Diabete Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Injectable Drugs For Type-2 Diabete Market Perspective (2021-2032)
  2. 3.2 Global Injectable Drugs For Type-2 Diabete Growth Trends by Region
  3. 3.2.1 Global Injectable Drugs For Type-2 Diabete Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Injectable Drugs For Type-2 Diabete Market Size by Region (2021-2026)
  5. 3.2.3 Global Injectable Drugs For Type-2 Diabete Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Injectable Drugs For Type-2 Diabete Revenue by Players
  2. 4.1.1 Global Injectable Drugs For Type-2 Diabete Revenue by Players (2021-2026)
  3. 4.1.2 Global Injectable Drugs For Type-2 Diabete Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Injectable Drugs For Type-2 Diabete Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Injectable Drugs For Type-2 Diabete Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Injectable Drugs For Type-2 Diabete Key Players Headquarters & Area Served
  7. 4.4 Global Injectable Drugs For Type-2 Diabete Players, Product Type & Application
  8. 4.5 Global Injectable Drugs For Type-2 Diabete Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Injectable Drugs For Type-2 Diabete Market CR5 and HHI
  11. 4.6.3 2025 Injectable Drugs For Type-2 Diabete Tier 1, Tier 2, and Tier 3
5 Injectable Drugs For Type-2 Diabete Market Size by Type
  1. 5.1 Global Injectable Drugs For Type-2 Diabete Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Injectable Drugs For Type-2 Diabete Revenue by Type (2021-2032)
  3. 5.3 Global Injectable Drugs For Type-2 Diabete Revenue Market Share by Type (2021-2032)
6 Injectable Drugs For Type-2 Diabete Market Size by Application
  1. 6.1 Global Injectable Drugs For Type-2 Diabete Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Injectable Drugs For Type-2 Diabete Revenue by Application (2021-2032)
  3. 6.3 Global Injectable Drugs For Type-2 Diabete Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sanofi
  2. 7.1.1 Sanofi Company Information
  3. 7.1.2 Sanofi Business Overview
  4. 7.1.3 Sanofi Injectable Drugs For Type-2 Diabete Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sanofi Injectable Drugs For Type-2 Diabete Product Portfolio
  6. 7.1.5 Sanofi Recent Developments
  7. 7.2 Merck
  8. 7.2.1 Merck Company Information
  9. 7.2.2 Merck Business Overview
  10. 7.2.3 Merck Injectable Drugs For Type-2 Diabete Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Merck Injectable Drugs For Type-2 Diabete Product Portfolio
  12. 7.2.5 Merck Recent Developments
  13. 7.3 Eli Lilly
  14. 7.3.1 Eli Lilly Company Information
  15. 7.3.2 Eli Lilly Business Overview
  16. 7.3.3 Eli Lilly Injectable Drugs For Type-2 Diabete Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Eli Lilly Injectable Drugs For Type-2 Diabete Product Portfolio
  18. 7.3.5 Eli Lilly Recent Developments
  19. 7.4 GSK
  20. 7.4.1 GSK Company Information
  21. 7.4.2 GSK Business Overview
  22. 7.4.3 GSK Injectable Drugs For Type-2 Diabete Revenue and Gross Margin (2021-2026)
  23. 7.4.4 GSK Injectable Drugs For Type-2 Diabete Product Portfolio
  24. 7.4.5 GSK Recent Developments
  25. 7.5 AstraZeneca
  26. 7.5.1 AstraZeneca Company Information
  27. 7.5.2 AstraZeneca Business Overview
  28. 7.5.3 AstraZeneca Injectable Drugs For Type-2 Diabete Revenue and Gross Margin (2021-2026)
  29. 7.5.4 AstraZeneca Injectable Drugs For Type-2 Diabete Product Portfolio
  30. 7.5.5 AstraZeneca Recent Developments
  31. 7.6 Novo Nordisk
  32. 7.6.1 Novo Nordisk Company Information
  33. 7.6.2 Novo Nordisk Business Overview
  34. 7.6.3 Novo Nordisk Injectable Drugs For Type-2 Diabete Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Novo Nordisk Injectable Drugs For Type-2 Diabete Product Portfolio
  36. 7.6.5 Novo Nordisk Recent Developments
  37. 7.7 Boehringer Ingelheim
  38. 7.7.1 Boehringer Ingelheim Company Information
  39. 7.7.2 Boehringer Ingelheim Business Overview
  40. 7.7.3 Boehringer Ingelheim Injectable Drugs For Type-2 Diabete Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Boehringer Ingelheim Injectable Drugs For Type-2 Diabete Product Portfolio
  42. 7.7.5 Boehringer Ingelheim Recent Developments
8 North America
  1. 8.1 North America Injectable Drugs For Type-2 Diabete Revenue (2021-2032)
  2. 8.2 North America Injectable Drugs For Type-2 Diabete Revenue by Type (2021-2032)
  3. 8.2.1 North America Injectable Drugs For Type-2 Diabete Revenue by Type (2021-2026)
  4. 8.2.2 North America Injectable Drugs For Type-2 Diabete Revenue by Type (2027-2032)
  5. 8.3 North America Injectable Drugs For Type-2 Diabete Revenue Share by Type (2021-2032)
  6. 8.4 North America Injectable Drugs For Type-2 Diabete Revenue by Application (2021-2032)
  7. 8.4.1 North America Injectable Drugs For Type-2 Diabete Revenue by Application (2021-2026)
  8. 8.4.2 North America Injectable Drugs For Type-2 Diabete Revenue by Application (2027-2032)
  9. 8.5 North America Injectable Drugs For Type-2 Diabete Revenue Share by Application (2021-2032)
  10. 8.6 North America Injectable Drugs For Type-2 Diabete Revenue by Country
  11. 8.6.1 North America Injectable Drugs For Type-2 Diabete Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Injectable Drugs For Type-2 Diabete Revenue by Country (2021-2026)
  13. 8.6.3 North America Injectable Drugs For Type-2 Diabete Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Injectable Drugs For Type-2 Diabete Revenue (2021-2032)
  2. 9.2 Europe Injectable Drugs For Type-2 Diabete Revenue by Type (2021-2032)
  3. 9.2.1 Europe Injectable Drugs For Type-2 Diabete Revenue by Type (2021-2026)
  4. 9.2.2 Europe Injectable Drugs For Type-2 Diabete Revenue by Type (2027-2032)
  5. 9.3 Europe Injectable Drugs For Type-2 Diabete Revenue Share by Type (2021-2032)
  6. 9.4 Europe Injectable Drugs For Type-2 Diabete Revenue by Application (2021-2032)
  7. 9.4.1 Europe Injectable Drugs For Type-2 Diabete Revenue by Application (2021-2026)
  8. 9.4.2 Europe Injectable Drugs For Type-2 Diabete Revenue by Application (2027-2032)
  9. 9.5 Europe Injectable Drugs For Type-2 Diabete Revenue Share by Application (2021-2032)
  10. 9.6 Europe Injectable Drugs For Type-2 Diabete Revenue by Country
  11. 9.6.1 Europe Injectable Drugs For Type-2 Diabete Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Injectable Drugs For Type-2 Diabete Revenue by Country (2021-2026)
  13. 9.6.3 Europe Injectable Drugs For Type-2 Diabete Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Injectable Drugs For Type-2 Diabete Revenue (2021-2032)
  2. 10.2 China Injectable Drugs For Type-2 Diabete Revenue by Type (2021-2032)
  3. 10.2.1 China Injectable Drugs For Type-2 Diabete Revenue by Type (2021-2026)
  4. 10.2.2 China Injectable Drugs For Type-2 Diabete Revenue by Type (2027-2032)
  5. 10.3 China Injectable Drugs For Type-2 Diabete Revenue Share by Type (2021-2032)
  6. 10.4 China Injectable Drugs For Type-2 Diabete Revenue by Application (2021-2032)
  7. 10.4.1 China Injectable Drugs For Type-2 Diabete Revenue by Application (2021-2026)
  8. 10.4.2 China Injectable Drugs For Type-2 Diabete Revenue by Application (2027-2032)
  9. 10.5 China Injectable Drugs For Type-2 Diabete Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Injectable Drugs For Type-2 Diabete Revenue (2021-2032)
  2. 11.2 Asia Injectable Drugs For Type-2 Diabete Revenue by Type (2021-2032)
  3. 11.2.1 Asia Injectable Drugs For Type-2 Diabete Revenue by Type (2021-2026)
  4. 11.2.2 Asia Injectable Drugs For Type-2 Diabete Revenue by Type (2027-2032)
  5. 11.3 Asia Injectable Drugs For Type-2 Diabete Revenue Share by Type (2021-2032)
  6. 11.4 Asia Injectable Drugs For Type-2 Diabete Revenue by Application (2021-2032)
  7. 11.4.1 Asia Injectable Drugs For Type-2 Diabete Revenue by Application (2021-2026)
  8. 11.4.2 Asia Injectable Drugs For Type-2 Diabete Revenue by Application (2027-2032)
  9. 11.5 Asia Injectable Drugs For Type-2 Diabete Revenue Share by Application (2021-2032)
  10. 11.6 Asia Injectable Drugs For Type-2 Diabete Revenue by Country
  11. 11.6.1 Asia Injectable Drugs For Type-2 Diabete Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Injectable Drugs For Type-2 Diabete Revenue by Country (2021-2026)
  13. 11.6.3 Asia Injectable Drugs For Type-2 Diabete Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Injectable Drugs For Type-2 Diabete Revenue (2021-2032)
  2. 12.2 SAMEA Injectable Drugs For Type-2 Diabete Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Injectable Drugs For Type-2 Diabete Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Injectable Drugs For Type-2 Diabete Revenue by Type (2027-2032)
  5. 12.3 SAMEA Injectable Drugs For Type-2 Diabete Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Injectable Drugs For Type-2 Diabete Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Injectable Drugs For Type-2 Diabete Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Injectable Drugs For Type-2 Diabete Revenue by Application (2027-2032)
  9. 12.5 SAMEA Injectable Drugs For Type-2 Diabete Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Injectable Drugs For Type-2 Diabete Revenue by Country
  11. 12.6.1 SAMEA Injectable Drugs For Type-2 Diabete Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Injectable Drugs For Type-2 Diabete Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Injectable Drugs For Type-2 Diabete Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst